Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narrative review synthesizing evidence from phase III trials and biomarker studies to inform clinical decision-making about adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable NSCLC, without reporting original trial data or meta-analysis.
Single-centre retrospective case series of 8 patients describing clinicopathological features and immune markers after sarcomatoid transformation; no control group, no comparative analysis, and no clinical outcomes reported.
Retrospective single-centre imaging cohort with exploratory endpoints and modest sample size; key finding (delta torso fat volume) failed validation in temporally aligned subgroup analysis and authors acknowledge need for further validation.
A single case report with serial molecular profiling showing clonal evolution under treatment; descriptive and hypothesis-generating but lacking comparative data, control arm, or generalizable evidence of clinical benefit.
Proof-of-concept feasibility study in 20 patients demonstrating technical workflow validation and preliminary dosimetric advantages of a novel functional imaging approach, requiring confirmation in larger, prospective trials before clinical adoption.
Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.
A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.
A single case report integrated with bibliometric review and exploratory bioinformatic analysis of gene expression datasets; no clinical trial, no new diagnostic or therapeutic validation, and no quantitative evidence of intervention efficacy beyond one patient's response.